Transient Myocardial ThICKENING IN CATS Associated with Heart Failure


Background: Cats with hypertrophic cardiomyopathy (HCM) and congestive heart failure (CHF) can have resolution of both left ventricular hypertrophy and CHF.

Objectives: To describe the clinical characteristics of cats with transient myocardial thickening (TMT) and CHF compared with a control population of cats without resolution of HCM.

Animals: A total of 21 cats with TMT, 21 cats with HCM.

Methods: Retrospective study. Clinical records at 4 veterinary centers were searched for TMT cases and a control group of cats with HCM and CHF. TMT was defined as initial maximal left ventricular wall thickness (LVWT) ≥ 6 mm with left-sided CHF, with subsequent resolution of CHF, reduction in left atrium/aorta (LA/Ao), and LVWT=≤5.5 mm. HCM was defined as persistent LVWT ≥ 6 mm.

Results: Cats with TMT were younger (2 [0.4–11.4] years) than cats with HCM (8 [1.6–14] years) (P < 0.0001), and antecedent events were more common (15/21 versus 6/21, respectively) (P = 0.01). In cats with TMT, LVWT normalized from 6.8 [6.0–9.7] mm to 4.8 [2.8–5.3] mm and LA/Ao decreased from 1.8 [1.6–2.3] to 1.45 [1.2–1.7] after a mean interval of 3.3 (95% CI: 1.8–4.7) months. CHF recurred in 1 of 21 TMT and 15 of 21 cats with HCM. Cardiac treatment was discontinued in 20 of 21 cats with TMT and 0 of 21 HCM cats. All cats with TMT survived, whereas 8 of 19 cats with HCM died during the study period.

Conclusions and Clinical Importance: TMT occurs in younger cats, and antecedent events are common. The prognosis is better in cats with CHF associated with TMT than HCM.

Key words: HCM phenocopy; Hypertrophic cardiomyopathy; Myocarditis; Takotsubo cardiomyopathy.

A hypertrophic cardiomyopathy (HCM) phenotype is characterized by increased left ventricular wall thickness (LVWT) in the absence of abnormal loading conditions capable of producing a similar degree of ventricular thickening.1,2 Myocardial wall thickness depends on 3 elements: the number of myocytes, myocyte size, and the volume of the interstitial space.3,4 In HCM, the increased LVWT is mediated by an increase in mass of individual myocytes and interstitial fibrous connective tissue,5 with the former being the most important component.3,4,6 Other diseases can mimic HCM by causing an increase in LVWT that is not due to myocyte hypertrophy or hyperplasia, such as intracellular accumulation of metabolic products (storage diseases) or interstitial infiltration of proteins, cells or fluid, such as in amyloidosis or myocarditis.7,8 These conditions represent up to 10% of all adult human cases with an HCM phenotype.7 In cats, an HCM phenotype has been described with endocrine disorders, such as hyperthyroidism or acromegaly, dehydration (pseudohypertrophy), and infiltrative disease (cardiac lymphoma).8–11 It is not known whether metabolic diseases or inflammatory disease are responsible for the abnormal phenotype seen in some cats diagnosed with HCM.

Cats with HCM and congestive heart failure (CHF) are generally reported to have a poor prognosis.12,13 We were aware of anecdotal reports of cats presenting with...
HCM and CHF that appeared to have a good prognosis, and a longitudinal echocardiographic study conducted by one of the authors (LW) confirmed that in some cats, apparent left ventricular hypertrophy had resolved by subsequent echocardiographic examinations (unpublished data). Furthermore, it has been suggested that cats with this clinical course are often young and have a history of an antecedent event, such as general anesthesia for neutering within days of presentation with CHF. As reverse remodeling with normalization of cardiac structure and function is not an expected outcome in HCM, these clinical observations describe a transient form of myocardial thickening associated with CHF in cats. Transient myocardial thickening (TMT) mimicking HCM has been described in some forms of acute/fulminant myocarditis in humans and in atypical cases of stress-induced (Takotsubo) cardiomyopathy. In both situations, the increased LVWT is associated with myocardial edema.

The aims of this study were to identify case details of cats with TMT and CHF from multiple veterinary cardiologists and describe their clinical and echocardiographic characteristics. Additionally, the clinical and echocardiographic features of cats with TMT were compared with a control population of cats with HCM and CHF, to identify characteristics at presentation that might distinguish cats with TMT from HCM.

Materials and Methods

This study was approved by the Clinical Research Ethical Review Board of the Royal Veterinary College (URN 2015–1397). The medical records and echocardiographic database of 4 referral centers (Royal Veterinary College, Vetsuisse Faculty, Hериofor Veterinary Referrals, and North Downs Specialists Referrals) were searched for cats diagnosed as HCM associated with CHF that showed normalization of LVWT over time. TMT cases were defined as cats with at least 2 echocardiographic examinations that had increased LVWT (LVWT ≥ 6 mm) and left atrial dilatation (left atrium to aorta ratio [LA/Ao] ≥ 1.6) with left-sided CHF at presentation but showed subsequent normalization of LVWT (LVWT < 5.5 mm) and left atrial size. Additionally, cats with left ventricular fractional shortening <40% or with evidence of focal left ventricular wall thinning with hypokinetic or dyskinetic myocardial segments at their final echocardiographic examination were excluded from the TMT group. A control group of cats with HCM was selected from the medical records and echocardiographic database at each center involved in the study. Cats with at least 2 echocardiographic examinations at least 5 months apart with left atrial dilatation (LA/Ao ≥ 1.6) and left-sided CHF on presentation and persistently increased LVWT (LVWT ≥ 6 mm) were selected as control HCM cats. All cats had CHF documented on thoracic radiographs or echocardiographic records included normal left atrial size (LA/Ao < 1.6) and the presence of systemic diseases known to affect the cardiovascular system, such as hyperthyroidism (all cats >8 years of age had T4 measured), systemic hypertension (systolic blood pressure ≥160 mmHg), diabetes mellitus, and chronic kidney disease (IRIS Stage >II).

Clinical Data

Additional data collected from the medical and echocardiographic records included age at diagnosis, sex, breed, presenting clinical signs, heart rate, respiratory rate, temperature, presence of a murmur, gallop or arrhythmia (and ECG diagnosis when available), and systolic blood pressure at presentation. In addition, thoracic radiographic findings (ie pulmonary edema, pleural effusion, or both), number of echocardiographic examinations performed, treatment, and any clinical pathology results available at presentation, such as cardiac biomarkers, complete blood count, serum chemistry, or serology for Toxoplasma gondii, Bartonella henselae, or FIV/FeLV, were recorded. The medical history of each cat was carefully evaluated for the presence of antecedent events, defined as any new medication, general anesthesia, and/or traumatic incident occurring within 14 days of presentation with CHF.

Outcome Data

Medical records were additionally reviewed for relapses of CHF, aortic thromboembolism, and cardiac death (death or euthanasia because of signs of CHF and/or aortic thromboembolism, or sudden death). In cases where treatment was discontinued, the duration of treatment was determined from the discharge date from hospital until all cardiac treatment was stopped. At the time of data collection (September 2015 to September 2016), owners of
Twenty-one TMT cases were identified in the 4 centers, and 21 HCM cases were selected as control group. The frequency of TMT cases seen at the 4 centers ranged between 1 and 4 cases every 2 years. Cats with TMT were younger (2 [0.4–11.4] years) than cats with HCM (8 [1.6–14] years), \( P < 0.0001 \). Males were over-represented in the TMT group (18 of 21 cats were male versus 10 of 21 males in the TMT group, \( P = 0.02 \)). Cats with HCM were also heavier than cats with TMT (\( P = 0.04 \)) Several breeds were represented in both groups with equal distribution. Domestic shorthair (DSH) was the most common breed (10 DSH with TMT and 14 DSH with HCM). The TMT population also included 4 British shorthair, 2 Ragdoll, and 2 Domestic Long Hair. The HCM population also included 2 British Shorthair and 2 Maine Coon. Other breeds included 1 Birman, 1 Russian Blue and 1 Sphynx in the TMT group and 1 Maine coon and 1 Exotic Shorthair in the HCM group. Antecedent events were identified in 71% of cats with TMT (15/21) and 29% of cats with HCM (6/21, \( P = 0.01 \)). In the TMT group, the most frequent antecedent event was general anesthesia (7 cats) followed by road traffic accident (2 cats). Anesthesia was performed for ovariohysterectomy (3 cats), and placement of indwelling urinary catheter, extraction of intestinal foreign body, tooth extraction, and draining abscess (1 cat each). Other antecedent events included vaccination, bite wound, pneumonia, fever of unknown origin, fever with thoracolumbar pain, and abdominal pain with vomiting (1 cat each). A range of drug combinations were administered during these events, including antibiotics (\( n = 12 \)), NSAIDs (\( n = 7 \)), opioids (\( n = 5 \)), fluids IV (\( n = 4 \)), corticosteroids (\( n = 3 \)), bronchodilators (\( n = 2 \), and antacids (\( n = 1 \)). In the HCM group, antecedent events included general anesthesia, eye prolapse, vaccination, abscess, and anorexia (1 cat each). Medications administered to the HCM group included antibiotics (\( n = 4 \)), corticosteroids (\( n = 2 \)), antiemetics (\( n = 2 \)), and bronchodilators (\( n = 1 \)). There were no differences between groups in the other clinical examination variables evaluated (Table 1).

### Results

A total of 174 echocardiographic scans were evaluated from the 42 cats enrolled in the study. Cats with TMT had a median of 3 [2–7] scans and cats with HCM 4 [2–9] scans performed during the study period. The time elapsed between the first and last echo was 8 [1.0–57] months for the whole population and 6 [1.1–57] months for cats with TMT and 10 [5–48] months for cats with HCM. At presentation, cats with TMT had thinner left ventricular walls than cats with HCM (\( P < 0.0001 \)) (Table 2, Fig 1). Similarly, at presentation, cats with TMT had smaller left atria than cats with HCM (\( P < 0.0001 \)) (Table 2, Fig 1). In cats with TMT, after a median period of 3.3 (95% CI: 1.8–4.7) months, the LVWT normalized (Fig 2). Left atrial size decreased over time in the TMT group, while it remained severely dilated in the HCM group (Table 3, Fig 1). Left atrial fractional shortening was reduced in both groups at presentation but improved significantly in the TMT group over time (\( P = 0.001 \)), while it remained markedly reduced in the HCM group (\( P = 0.67 \)) (Table 3, Fig 3).

Cardiac troponin I (cTnI) was available in 13 of 21 cats with TMT and 6 of 21 cats with HCM at presentation. Median cTnI was 2.1 [0.05–63.8] ng/mL in cats with TMT and 1.2 [0.3–6.4] ng/mL in HCM (\( P = 0.2 \)). In 7 of 13 cats with TMT, cTnI was repeated at the

### Echocardiographic Data

#### Table 1. Summary of additional clinical characteristics and laboratory parameters at initial presentation in cats with TMT and HCM

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>TMT</th>
<th>HCM</th>
<th>( P ) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight (kg)</td>
<td>4.1 (1.9–6.2)</td>
<td>4.8 (2.7–7.2)</td>
<td>0.04</td>
</tr>
<tr>
<td>Heart rate (bpm)</td>
<td>180 (90–250)</td>
<td>190 (155–220)</td>
<td>0.15</td>
</tr>
<tr>
<td>Respiratory rate (breaths per minute)</td>
<td>64 (40–104)</td>
<td>58 (40–130)</td>
<td>0.8</td>
</tr>
<tr>
<td>Murmur (% yes)</td>
<td>7/21 (33%)</td>
<td>9/15 (60%)</td>
<td>0.18</td>
</tr>
<tr>
<td>Arrhythmia (% yes)</td>
<td>2/21 (10%)</td>
<td>3/17 (18%)</td>
<td>0.64</td>
</tr>
<tr>
<td>Pulmonary edema/pleural effusion/both</td>
<td>6/2/13</td>
<td>11/1/9</td>
<td>0.28</td>
</tr>
<tr>
<td>Hematocrit (%)</td>
<td>33% (15–54)</td>
<td>35% (24–51)</td>
<td>1.0</td>
</tr>
<tr>
<td>Urea (mmol/L)</td>
<td>12.8 (3.9–34)</td>
<td>11.4 (6.6–20.5)</td>
<td>0.27</td>
</tr>
<tr>
<td>Furosemide dose at discharge (mg/kg/d)</td>
<td>2.1 (0.9–5.4)</td>
<td>2.0 (1.4–4.0)</td>
<td>0.99</td>
</tr>
</tbody>
</table>

AF, atrial fibrillation; 3AVB, third-degree atrioventricular block; FAT, focal atrial tachycardia; HCM, hypertrophic cardiomyopathy; TMT, transient myocardial thickening; VPCs, ventricular premature complexes.
time of LVWT normalization. Median cTnI was elevated at presentation and normalized once myocardial thickening resolved (2.1 [0.05–63.8] ng/mL versus 0.01 [0.0–0.3] ng/mL, P = .018) (reference <0.16 ng/mL). 36 IgM and IgG antibodies for *T. gondii* and *B. henselae* were measured in 4 cats with TMT. *Toxoplasma* was negative in 4 of 4 and *Bartonella* was positive in 3 of 4 cats (IgM 1:160–640, reference <1:20; IgG 80–640, reference <1:20), although only 1 of 3 cats was treated for *Bartonella*.

Cats from both groups received various combinations of cardiac medications at the time of CHF diagnosis. All cats received furosemide but a greater proportion of cats with HCM (19/21) than cats with TMT (12/21) received medications in addition to furosemide (eg diltiazem, atenolol, spironolactone, pimobendan, and ACE inhibitors, P = .03). Additional characteristics of the study population are presented in Table 1.

**Long-term Follow-up in Cats with TMT**

After normalization of LVWT to <5.5 mm, 15 of 21 cats with TMT had a further follow-up scan up to 5 [1–57] months later. In all cases, there was a further decrease in LVWT from a median LVWT of 5.1 [3.8–5.4] mm to 4.8 [2.8–5.3] mm (P = .02, Fig 4), while left ventricular systolic function and left atrial size remained normal.

**Outcome Data**

Congestive heart failure recurred in 1 of 21 cats with TMT shortly after discharge, and all cats were alive at the time of writing. CHF recurred in 15 of 21 cats with HCM; 2 of 21 had an aortic thromboembolus; and 8 of 19 died during the study period (2 cats were lost to follow-up). In 20 of 21 cats with heart disease during the duration of the study or until death. In 1 cat with TMT, administration of clopidogrel and aspirin were not stopped, even though the heart was normal on the last echocardiographic examination, as the cat had a previous suspicion of a thrombus on the mitral valve. The cat was lost to follow-up.

**Discussion**

In this study, we describe a transient form of myocardial disease in cats that mimics HCM and is associated with CHF but has an excellent long-term prognosis. TMT is a relatively uncommon condition that seems to affect young cats, often with a history of an antecedent event. 

The underlying pathophysiology causing the transient ventricular wall thickening is unknown, but in view of the fast reverse remodeling seen in our cases, myocardial edema and/or transient cellular infiltration might be responsible. Acute myocarditis in humans can cause TMT that resembles HCM at initial presentation. 2,7,17–19,25,26,37–40 In these cases, the increased ventricular wall thickness was shown to be associated with severe myocardial interstitial edema.7,24–26 Myocardial edema is one of the main features of the inflammatory response in acute myocarditis in humans.41 Myocarditis

---

**Table 2. Echocardiographic variables at initial presentation in cats with TMT and HCM**

<table>
<thead>
<tr>
<th>Variable</th>
<th>TMT</th>
<th>HCM</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>LVWT (mm)</td>
<td>6.8 (6.0–9.7)</td>
<td>8.1 (6.0–12.3)</td>
<td>0.001</td>
</tr>
<tr>
<td>LA/Ao</td>
<td>1.8 (1.6–2.3)</td>
<td>2.4 (1.6–3.4)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Papillary muscle hypertrophy (% yes)</td>
<td>13/21 (62%)</td>
<td>14/21 (67%)</td>
<td>.75</td>
</tr>
<tr>
<td>Symmetric wall thickening (%yes)</td>
<td>20/21 (95%)</td>
<td>16/21 (76%)</td>
<td>.18</td>
</tr>
<tr>
<td>SAM (% yes)</td>
<td>6/21 (29%)</td>
<td>6/21 (29%)</td>
<td>1.0</td>
</tr>
<tr>
<td>Pericardial effusion (% yes)</td>
<td>9/21 (43%)</td>
<td>8/21 (38%)</td>
<td>0.5</td>
</tr>
<tr>
<td>SEC (% yes)</td>
<td>4/21 (19%)</td>
<td>8/21 (38%)</td>
<td>0.3</td>
</tr>
</tbody>
</table>

LVWT, left ventricular wall thickness; LA/Ao, left atrium to aorta ratio; SAM, systolic cranial motion; SEC, spontaneous echocardiographic contrast.
is poorly described in small animals but increased LVWT can occur with toxoplasma myocarditis, myocarditis caused by FIV, and in eosinophilic myocarditis. The increased LVWT can normalize if the patient survives the acute CHF episode, as described in a cat with toxoplasma myocarditis. Cats with TMT were younger than cats with HCM (median age 1.7 versus 8 years). In people, acute

Table 3. Selective echocardiographic variables at presentation and final echocardiographic examination in cats with TMT and HCM

<table>
<thead>
<tr>
<th></th>
<th>TMT</th>
<th>HCM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Initial Echo</td>
<td>Final Echo</td>
</tr>
<tr>
<td>LVWT (mm)</td>
<td>6.8 (6.0–9.7)</td>
<td>4.8 (2.8–5.3)</td>
</tr>
<tr>
<td>LA/Ao</td>
<td>1.8 (1.6–2.3)</td>
<td>1.45 (1.2–1.7)</td>
</tr>
<tr>
<td>LAFS%</td>
<td>17 (4.3–21)</td>
<td>27 (15–49.6)</td>
</tr>
</tbody>
</table>

Cats with TMT showed a marked and clinically significant decrease in LVWT and LA size over time. LA/Ao, left atrium to aorta ratio; LVWT, left ventricular wall thickness; LAFS%, left atrial fractional shortening; LVWT, left ventricular wall thickness.

Fig 2. Right parasternal long-axis (A, B, E, F) and short-axis views (C, D, G, H) at end-diastolic frame from 2 TMT cases at initial presentation (A, C and E, G) and 7 months later (B, D and F, H). The initial severely increased left ventricular wall thickness (A, C, E, G) and mild pericardial effusion (E, G) resolved completely, with a morphologically normal heart 7 months later.
myocarditis is most common in young individuals, with an average age of 10 years reported in 43 patients from 9 different publications (95% CI: 0.45 – 19.6). It is possible that TMT is a form of myocarditis as described in people. In our study, very few cats had serological testing for Bartonella and Toxoplasma done which hinders any meaningful conclusion, especially considering the high prevalence of Bartonella seropositivity in healthy cats. In humans, a cause for myocarditis is not identified in the majority of cases, although various infectious agents, drugs (eg hypersensitivity reactions), and toxins have all been reported to cause myocarditis. Viral infections are considered to be the most common underlying cause.

The majority of cats with TMT in our study had events preceding their presentation in CHF, and these were more common in cats with TMT than HCM (71% of TMT versus 29% of HCM cases). Stalis et al described very similar antecedent stressful events to those observed in our TMT population in 75% of young cats with endomyocarditis. Many cats received drugs before presenting with TMT, and hypersensitivity drug reactions are a known cause of myocarditis in humans. Alternatively, the myocardial changes observed could potentially be a consequence of a catecholamine surge caused by emotional or physical triggers. In humans, catecholamines may cause toxic myocarditis in cases of phaeocromocytoma or stress-induced (Takotsubo) cardiomyopathy due to an exaggerated sympathetic stimulation. Takotsubo cardiomyopathy is a transient left ventricular dysfunction most frequently characterized by an apical “ballooning” phenotype in people, but myocardial edema mimicking HCM has also been described in Takotsubo cases, and differentiation from true HCM requires advanced cross-sectional imaging. TMT could then potentially be caused by an emotional or physical stress associated with the reported antecedent events.

Cardiac troponin I was markedly elevated in most cats with TMT where it was assessed. Blood concentration of cardiac troponins is highly sensitive and specific for cardiac myocyte injury, and highly suggestive of acute myocarditis when other causes of severe myocardial injury have been excluded. However, serum concentration of cardiac troponins is elevated in Takotsubo patients, and the differentiation between these 2 entities might require cardiac magnetic resonance (CMR) imaging. cTnI might potentially be useful to differentiate TMT from HCM cases, although there is likely to be overlap between groups. Cats with HCM can also have substantially elevated serum cTnI concentrations, and some cats with TMT have normal to mildly increased cTnI.

At presentation, cats with TMT had thinner left ventricular walls than cats with HCM. If myocardial edema is indeed the mechanism behind increased wall thickness in TMT, it makes sense that the degree of wall thickening is limited and potentially not as extreme as seen with left ventricular hypertrophy in HCM cases. There was marked overlap in LVWT between the 2 groups, and this feature cannot be used to differentiate cats with TMT from HCM.

The cats with TMT had mild increases in left atrial size and decreased atrial fractional shortening that normalized over time. These findings suggest an acute myocardial insult without time for the left atrium to adapt to the increased filling pressures (ie dilate), which caused acute increase in left atrial and pulmonary capillary pressure resulting in acute pulmonary edema. Cats with an HCM phenotype and CHF following corticosteroid administration can show normalization of the morphological cardiac changes over time and can have an excellent long-term prognosis. This has been postulated to be a unique form of CHF induced by corticosteroids. The clinical findings and clinical course of cats with corticosteroid-associated CHF were very similar to our population, although older (9.3 [5.6–12.4])
than the cats in this study (2 [0.4–11.4] years). In our study, there was no difference in the proportion of cats receiving corticosteroids between the TMT and HCM populations. The cats with corticosteroid-associated CHF received these drugs for a variety of medical reasons, including events that would have been classified as antecedent stressful events in our study.

Based on our results, there were no clinical or echocardiographic characteristics at presentation differentiating TMT from HCM. Besides the younger age of cats with TMT and the presence of antecedent events, the different progression over time may be the only way of differentiating TMT from HCM, where cats with TMT show reverse remodeling with normalization of LVWT and left atrial size, while cats with HCM show a progressive deterioration of their cardiac function. CMR imaging and endomyocardial biopsy are both used in humans to make the diagnosis of myocarditis, with biopsy being the gold standard.\(^{45}\)

Transient myocardial thickening should be considered as a differential diagnosis in cats with an HCM phenotype, especially in young cats with a history of an antecedent event. Additionally, the perception of a poor prognosis in symptomatic HCM (specifically with CHF) and the need for lifelong treatment may discourage clinicians and owners from attempting treatment and might result in premature euthanasia. The identification and description of a transient form of heart failure in cats associated with an excellent prognosis may have a profound impact on clinical decisions made by veterinarians when faced with a young cat with severe CHF. Furthermore, lifelong treatment may not be appropriate for all cats with an initial diagnosis of decompensated HCM.

This was a retrospective study and, as such, has some inherent limitations. More advanced echocardiographic parameters, such as tissue Doppler imaging and diastolic function evaluation, were not systematically assessed in our population of cats. These might have helped distinguishing TMT from HCM cats, although the echocardiographic variables assessed in our study are the ones most commonly used in routine clinical practice. Another limitation is that echocardiography was performed at different time points after presentation, and some cats received diuretics before the initial echocardiographic assessment. These were cats in critical condition presented in acute left-side CHF that hindered detailed echocardiographic assessment. Myocardial thickening could have therefore been caused by pseudohypertrophy due to hypovolemia secondary to diuretic treatment or as a result of some of the reported antecedent events. However, we believe it is unlikely that the increased LVWT in the cats with TMT was pseudohypertrophy, as left atrial enlargement was one of the inclusion criteria, and all cats showed complete resolution of clinical signs with diuretic treatment.

**Conclusions**

We describe a transient form of myocardial disease in cats that causes CHF but is associated with a better prognosis than expected for cats with HCM and CHF. TMT appears to preferentially affect young cats and often follows an antecedent event but is difficult to differentiate from HCM at presentation. The recognition of TMT could have an important impact in daily clinical cardiology, leading to clinicians and owners attempting treatment in cases classically thought to have a poor prognosis, and potentially avoiding premature euthanasia. Additionally, TMT might influence the definition of HCM and design of studies of HCM in cats.

**Footnote**

* SPSS 22.0.1, IBM Company, Chicago, IL.

**Acknowledgment**

JNM’s PhD was funded by Everts Luff Feline Endowment.

**Conflict of Interest Declaration:** Authors declare no conflict of interest.

**Off-label Antimicrobial Declaration:** Authors declare no off-label use of antimicrobials.

**References**


32. Payne JR, Brodbelt DC, Luis Fuentes V. Cardiomyopathy prevalence in 780 apparently healthy cats in rehoming centres (the CatScan study). J Vet Cardiol 2015;17(Suppl 1):S244–S257.


